Codexis Is Chasing a Blockbuster Opportunity. Can It Compete With Gene Therapies?
Genetic medicines and cellular therapies have an enormous potential to treat, and possibly cure, currently untreatable diseases. Nonetheless, it's important for investors to remember that "simpler" treatment options won't become obsolete just because gene therapy, gene editing, and immunotherapy approaches are becoming feasible.
Investors are hoping that the 'simple is better' approach proves true for Codexis (NASDAQ: CDXS). The company's first drug candidate, the enzyme-based CDX-6114, is being developed to treat a rare disease called phenylketonuria (PKU). Can the simpler approach of Codexis compete with a growing list of gene therapies that are also targeting the disease?
Image source: Getty Images.
Source Fool.com
